The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

(2010) Tamar Goren et al.   JOURNAL OF CLINICAL PHARMACOLOGY

MAO-B inhibitor know-how: Back to the pharm

(2009) P. A. LeWitt   NEUROLOGY

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

(2008) Lawrence W Elmer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease

(2008) William B. White et al.   HYPERTENSION

Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension

(2008) Yehonatan Sharabi et al.   MOVEMENT DISORDERS

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS